Clay Siegall Is Kicking Cancers Butt

In a recent interview with, founder and CEO of Seattle Genetics sat down to share his some of his secrets to success. Always passionate about helping others, Clay Siegall says he has always had a passion for medicine. The desire to fight illness and help others overcome disease is what led the entrepreneur to create Seattle Genetics.

After watching a loved one battle cancer first hand, Siegall was determined to make a difference and revolutionize the cancer treatment industry. Treatment is meant to help improve the quality of life, but Siegall recalls a worsening of his loved one’s condition following the start of treatment. As in most cases, the chemotherapy had also made the symptoms of the patient’s condition worse.

Fueled by the desire to make a change, he began researching other treatment options. To his surprise, the options seemed to be few and were not accessible to all patients. Seattle Genetics was not only created to improve the quality of cancer treatment but to also bridge the gap between proper education and diverse treatment options. Seattle Genetics uses a combination of monoclonal antibody-based therapies and anti-drug conjugates, or ACDs to help patients fight cancer. Unlike chemotherapy, ACDs target only the cells that cause cancer thus reducing the effects of toxins released during traditional chemotherapy.

After graduating from the University of Maryland with a bachelors degree in zoology, Sigeall went on to earn a Ph.D. in genetics from The George Washington University. His combination of compassion and education would serve as fuel in his fight to improve cancer treatment. The company’s newest development, brentuximab vedotin or ADCETRIS is making a breakthrough in the cancer treatment industry. Under the guidance of Dr. Clay Siegall, Seattle Genetics has established themselves as leaders in cancer treatment, and in healthcare. Currently, there are more than 20 new ACDs using Seattle Genetics technology in the clinical development stages. Since their 1998 launch, the company has raised more than $675 million towards research and the development of new treatment therapies.

Leave a Reply

Your email address will not be published. Required fields are marked *